Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for G2545C104 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Fairmount Funds Management LLC
13D/A
Amendment 2
|
16.5% |
7/20/2026
Event 7/16/2026
|
|
| Fairmount Funds Management LLC | 16.5% | ||
| Fairmount Healthcare Fund II L.P. | 16.5% | ||
| Peter Harwin | 16.5% | ||
| Tomas Kiselak | 16.5% | ||
|
Tang Capital Management LLC
13G/A
Amendment 1
|
4.2% |
5/15/2026
Event 3/31/2026
|
|
| Tang Capital Management, LLC | 4.2% | ||
| Kevin Tang | 4.2% | ||
| Tang Capital Partners, LP | 2.2% | ||
| Tang Capital Partners International, LP | 1.6% | ||
| Tang Capital Partners III, Inc | 0.3% | ||
| Tang Capital Partners IV, Inc | 0% | ||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 1
|
9.5% |
2/17/2026
Event 12/31/2025
|
|
| Venrock Healthcare Capital Partners III, L.P. | 9.5% | ||
| VHCP Co-Investment Holdings III, LLC | 9.5% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 9.5% | ||
| VHCP Management III, LLC | 9.5% | ||
| VHCP Management EG, LLC | 9.5% | ||
| Nimish Shah | 9.5% | ||
| Bong Y. Koh | 9.5% | ||
|
Vestal Point Capital, LP
13G
|
5.4% |
2/17/2026
Event 12/31/2025
|
|
| Vestal Point Capital, LP | 5.4% | ||
| Ryan Wilder | 5.4% | ||
|
FMR LLC
13G/A
Amendment 1
|
15.0% |
2/5/2026
Event 12/31/2025
|
|
| FMR LLC | 15.0% | ||
| Abigail P. Johnson | 15.0% | ||
|
ForGrowth III PA B.V.
13G
|
6.1% |
12/11/2025
Event 12/8/2025
|
|
| ForGrowth III PA B.V. | 6.1% | ||
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 6.1% | ||
| Forbion Growth III Management B.V. | 6.1% | ||
|
Fairmount Funds Management LLC
13D/A
Amendment 1
|
18.5% |
12/8/2025
Event 12/4/2025
|
|
| Fairmount Funds Management LLC | 18.5% | ||
| Fairmount Healthcare Fund II L.P. | 18.5% | ||
| Peter Evan Harwin | 18.5% | ||
| Tomas Kiselak | 18.5% | ||
|
Tang Capital Management LLC
13G
|
5.0% |
10/9/2025
Event 10/2/2025
|
|
| Tang Capital Management, LLC | 5.0% | ||
| Kevin Tang | 5.0% | ||
| Tang Capital Partners, LP | 2.8% | ||
| Tang Capital Partners International, LP | 2.2% | ||
| Tang Capital Partners III, Inc | 0% | ||
| Tang Capital Partners IV, Inc | 0% | ||
|
Logos Global Management LP
13G/A
Amendment 1
|
4.1% |
8/14/2025
Event 6/30/2025
|
|
| Logos Global Management LP | 4.1% | ||
| Logos Global Management GP LLC | 4.1% | ||
| Logos Global Master Fund LP | 0.7% | ||
| Logos GP LLC | 0.7% | ||
| Arsani William | 4.1% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 5
|
10.0% |
8/14/2025
Event 6/30/2025
|
|
| Biotechnology Value Fund L P | 5.1% | ||
| BVF I GP LLC | 5.1% | ||
| Biotechnology Value Fund II LP | 4.3% | ||
| BVF II GP LLC | 4.3% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 9.4% | ||
| BVF Partners L P/IL | 10.0% | ||
| BVF Inc/IL | 10.0% | ||
| Lampert Mark N | 10.0% | ||
|
Fairmount Funds Management LLC
13D
|
20.0% |
6/23/2025
Event 6/13/2025
|
|
| Fairmount Funds Management LLC | 20.0% | ||
| Fairmount Healthcare Fund II L.P. | 20.0% | ||
| Peter Evan Harwin | 20.0% | ||
| Tomas Kiselak | 20.0% |